Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals Limited has announced a proposed issue of 8,000,000 ordinary fully paid securities. This move is part of a placement or other type of issue, which is expected to impact the company’s capital structure and potentially enhance its market position by providing additional financial resources for its operations and strategic initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for various medical conditions. The company is known for its work in repurposing existing drugs to treat new indications, with a particular emphasis on inflammatory diseases and pain management.
Average Trading Volume: 872,229
Technical Sentiment Signal: Sell
Current Market Cap: A$124.6M
See more insights into PAR stock on TipRanks’ Stock Analysis page.